J&J restructuring to integrate R&D, marketing, ops

Last Friday, the New York Times reported that J&J has restructured, organizing its operations along three major categories of therapies:
  • treatments for pain, inflectious diseases, CNS, metabolic and cardiovascular diseases
  • immune-related
  • virology-related.
Overseeing all R&D, commercial and operations activites for the company's pharmaceuticals group will be Joseph Scodari.